NERVHealthcare · BiotechnologyThe 3 Wall Street analysts covering Minerva Neurosciences, Inc. hold a median 12-month price target of $10 — +141.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 32 of 100 as at 12 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Minerva Neurosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (79): The shares have been drifting up relative to others.
Issuance (5): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on NERV, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +141.0% from it.
Of the 20 most recent actions, 1 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 14 Aug 2026 | Jefferies | Upgrade | Buy | $7.50 → $10 |
| 15 Apr 2026 | Citizens | Initiates | Market Outperform | — |
| 15 Apr 2026 | Citizens | Initiates | Market Outperform | $14 |
| 12 Mar 2026 | HC Wainwright & Co. | Maintains | Neutral | — |
| 6 Nov 2025 | HC Wainwright & Co. | Maintains | Neutral | — |
| 26 Feb 2025 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 6 Nov 2024 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 7 Aug 2024 | HC Wainwright & Co. | Maintains | Neutral | — |
| 2 May 2024 | HC Wainwright & Co. | Maintains | Neutral | — |
| 27 Feb 2024 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 2 Aug 2023 | HC Wainwright & Co. | Maintains | Neutral | — |
| 16 May 2023 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 2 May 2023 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 9 Mar 2023 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 10 Nov 2022 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 17 Oct 2022 | JMP Securities | Downgrade | Market Perform | — |
| 4 Mar 2022 | HC Wainwright & Co. | Maintains | Buy | $10 → $5.00 |
| 8 June 2020 | HC Wainwright & Co. | Maintains | Buy | $20 → $10 |
| 19 Dec 2019 | H.C. Wainwright | Reiterates | Buy | — |
| 19 Dec 2019 | HC Wainwright & Co. | Reiterates | Buy | $22 → $20 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NERV appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 11 Sept 2026, Minerva Neurosciences, Inc. returned +94.8% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 69% of US stocks
Cheaper than 94% of US stocks
Cheaper than 81% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 98% of US stocks
Higher than 15% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Minerva Neurosciences, Inc. has a market value of $198.2M and an enterprise value of $194.6M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$394.3M.
Diluted earnings per share, trailing twelve months: $−28.87.
Free cash flow in the twelve months to 30 June 2026: −$26.2M.
Trailing P/E: 2.5×; forward P/E: −9.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Minerva Neurosciences, Inc. employs 7 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
| Company | Market cap | TKN rank |
|---|---|---|
| NERVMinerva Neurosciences, Inc. | $198.2M | 32 |
| ANTXAN2 Therapeutics, Inc. | $194.4M | 72 |
| ORMPOramed Pharmaceuticals, Inc. | $191.1M | 82 |
| VYGRVoyager Therapeutics, Inc. | $190.1M | 76 |
| ARMPArmata Pharmaceuticals, Inc. | $197.1M | 71 |
| NMRANeumora Therapeutics, Inc. | $189.3M | 36 |
| DTILPrecision BioSciences, Inc. | $197.9M | 68 |
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Minerva Neurosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Minerva Neurosciences announced that its management will participate in two upcoming investor conferences. The clinical-stage biopharmaceutical company focuses on therapies for central nervous system disorders.
Why it matters — The conference participation gives investors opportunities to hear directly from management about the company and its clinical programs.
Minerva Neurosciences reported financial results and business updates for the second quarter ended June 30, 2026. The confirmatory Phase 3 trial of roluperidone (MIN-101C19) is ongoing with topline efficacy data expected in the second half of 2027, and a Scientific Advisory Board of leading psychiatry and neuroscience experts has been established to guide the trial.
Why it matters — NERV watchers would care because progress updates on the confirmatory roluperidone Phase 3 trial, currently the only late-stage drug candidate for that high-need population, are central to the company's outlook.
The 3 Wall Street analysts covering Minerva Neurosciences, Inc. have a median 12-month price target of $10, with estimates ranging from $7 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 3 analysts covering Minerva Neurosciences, Inc., 2 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Minerva Neurosciences, Inc. 32 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 12 Sept 2026, Minerva Neurosciences, Inc. ranks 32 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (79 of 100).
No one can know that. What the data says: the median 12-month target from 3 analysts implies +141.0% from the last close, and Ticker Nerd's factor model ranks Minerva Neurosciences, Inc. 32 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Minerva Neurosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NERV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $14 over the next 12 months.
Minerva Neurosciences, Inc. returned +94.8% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Minerva Neurosciences Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders.
The most recent item we track (GlobeNewsWire, 28 Aug 2026): "Minerva Neurosciences to Participate in Two Upcoming Investor Conferences". Minerva Neurosciences announced that its management will participate in two upcoming investor conferences. The clinical-stage biopharmaceutical company focuses on therapies for central nervous system disorders.
Minerva Neurosciences Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders. Its current pipeline centers on roluperidone, a product candidate being studied for the treatment of negative symptoms in schizophrenia, and other CNS-related programs such as seltorexant. The company’s work is concentrated on advancing proprietary medicines through clinical development and regulatory pathways, with an emphasis on conditions where treatment options remain limited. Minerva Neurosciences serves a specialized role in the biopharmaceutical market by targeting neuropsychiatric and neurological diseases that affect patients, clinicians, and healthcare systems worldwide. Headquartered in Burlington, Massachusetts, Minerva Neurosciences operates as a research-driven company whose primary business is the development and commercialization of product candidates for complex brain and nervous system disorders.
CEO Dr. Remy Luthringer Ph.D. · 7 employees · United States · https://www.minervaneurosciences.com
